INTRODUCTION
============

The incidence of pancreatic cancer (PC) is increasing, and PC is now the fifth leading cause of cancer death in Japan.^[@r01]--[@r05]^ Because early detection and curative treatment of PC are very difficult, the 5-year survival rate is only 5.5%.^[@r06]^ This suggests that epidemiologic approaches to identifying PC high-risk groups have an important role in decreasing the number of PC deaths.

Possible risk factors for PC include advanced age, smoking, overweight, diabetes mellitus, and alcohol consumption.^[@r02],[@r07]--[@r10]^ A positive association between PC risk and a family history of PC has also been reported, suggesting the possible involvement of genetic factors in PC incidence.^[@r05],[@r10],[@r11]^ Recently, several reports have observed an association between polymorphisms in DNA repair genes and PC risk, particularly among smokers.^[@r12]--[@r20]^ Four major types of DNA repair system have been identified, namely base excision repair (BER), nucleotide excision repair, mismatch repair, and double-strand break repair.^[@r14],[@r21]--[@r23]^ With regard to the association between PC risk and DNA repair genes, genetic polymorphisms in the BER pathway are the most extensively investigated in molecular epidemiologic studies.^[@r14]^ However, most studies of the association between PC risk and BER gene polymorphisms have been conducted in white populations.

We conducted a case-control study in a Japanese population to evaluate the impact of genetic polymorphisms in BER pathways on PC risk among Asians. The study focused on 4 key genes in this repair pathway: X-ray repair cross-complementing group 1 (*XRCC1*), apurinic/apyrimidinic endonuclease (*APE1*), 8-oxoguanine DNA glycosylase (*OGG1*), and poly(ADP-ribose) polymerase 1 (*PARP1*).

METHODS
=======

Study subjects
--------------

The case subjects were 185 PC patients with no prior history of cancer who were diagnosed at Aichi Cancer Center Hospital (ACCH), Nagoya, Japan, between January 2001 and November 2005. The control subjects comprised 1465 randomly selected non-cancer ACCH outpatients, during the same period, who had no history of any cancer. All subjects were enrolled in the Hospital-based Epidemiological Research Program II at ACCH (HERPACC-II) at the time of their first visit to ACCH. The framework of HERPACC-II has been described elsewhere.^[@r24],[@r25]^ Briefly, all first-visit ACCH outpatients aged 20 to 79 years were asked to complete a self-administered questionnaire on their lifestyle before development of the presenting symptoms. Outpatients were also asked to provide a 7-mL blood sample. Approximately 95% of eligible subjects completed the questionnaire, and 50% provided blood samples. All data were loaded into the HERPACC database, which is periodically synchronized with the hospital cancer registry system. Approximately 35% of subjects were diagnosed with cancer within a year of the first visit. In the present study, we defined the case population as patients who received a diagnosis of PC within 1 year of the first visit, ie, we used the window period from first visit to final diagnosis of PC rather than prospectively identifying cases. A total of 75.7% of PC cases were histologically confirmed, among which 92.1% were diagnosed as having ductal adenocarcinoma. Our previous study showed that the lifestyle patterns of first-visit outpatients corresponded with those of individuals randomly selected from Nagoya's general population, which confirms the external validity of the study.^[@r26]^ The present study was approved by the Ethics Committee of Aichi Cancer Center, and informed consent was obtained at first visit from all participants.

Genotyping
----------

We examined 5 non-synonymous polymorphisms in BER pathway genes, namely rs1799782 (Arg194Trp) and rs25487 (Arg399Gln) in *XRCC1*, rs1130409 (Asp148Glu) in *APE1*, rs1052133 in *OGG1* (Ser326Cys), and rs1136410 (Val762Ala) in *PARP1*. In our study, these 5 single-nucleotide polymorphisms (SNPs) were selected on the basis of their association with cancer risk or their expected influence on BER systems.^[@r13],[@r14],[@r17]--[@r22],[@r27]--[@r29]^ DNA of each subject was extracted from the buffy coat fraction using a DNA Blood Mini Kit (Qiagen, Tokyo, Japan). All loci were examined by the TaqMan assay with probes and primers (Applied Biosystems, Foster City, CA, USA) and the Fluidigm EP1 SNP Genotyping 96.96 Dynamic Array (Fluidigm Corp., South San Francisco, CA, USA). Approximately 10% of subjects were examined in duplicate to confirm the consistency of genotyping.

Assessment of exposure
----------------------

Exposure to potential PC risk factors was assessed from responses to the self-administered questionnaire, which was completed before diagnosis during the first visit to ACCH and reviewed by trained interviewers. Subjects were specifically questioned about their lifestyle before the onset of presenting symptoms. Daily alcohol consumption in grams was determined by summing the amount of pure alcohol in the average daily consumption of Japanese *sake* (rice wine), *shochu* (distilled spirit), beer, wine, and whiskey. Cumulative smoking exposure was measured in pack-years (PYs), ie, the product of the average number of packs per day and the number of years of smoking. Height and body weight at baseline and weight at age 20 years were self-reported. Current body mass index (BMI) and BMI at age 20 were calculated by dividing the weight in kilograms by the height in meters squared. Family history of PC was considered positive when at least 1 parent or sibling had a history of PC.

Statistical analysis
--------------------

All statistical analyses were performed using Stata version 10 (Stata Corp., College Station, TX, USA). A *P*-value less than 0.05 was considered statistically significant. Differences in characteristics between cases and controls were assessed using the chi-square test. Odds ratios (ORs) and 95% CIs were estimated using an unconditional logistic regression model adjusted for potential confounders. Potential confounders considered in multivariate analysis were age, sex, PYs of smoking (\<5, ≥5 but \<20, ≥20 but \<40, or ≥40), drinking habit (nondrinker, \<23, ≥23 but \<46, or ≥46 g/day), current BMI (\<18.5, ≥18.5 but \<22.5, ≥22.5 but \<25, ≥25 but \<27.5, or ≥27.5 kg/m^2^), BMI at age 20 (\<18.5, ≥18.5 but \<22.5, ≥22.5 but \<25, ≥25 but \<27.5, or ≥27.5 kg/m^2^), history of diabetes mellitus (yes or no), and family history of PC (yes or no). Interactions between environmental factors and genotypes were assessed by using likelihood ratio tests within logistic regression models, with and without interaction terms. In haplotype analysis, we used haplotype-effects logistic regression for case-control data.^[@r30]^ This haplotype analysis uses phased and unphased SNP genotype data to estimate haplotype effects and haplotype--environment interactions in a case-control study.^[@r30],[@r31]^ It fits haplotype-effects logistic regression by using the retrospective likelihood method in a special case of a rare disease and a single candidate gene in the Hardy--Weinberg Equilibrium (HWE), under the assumption of gene--environment independence.^[@r30],[@r31]^ Accordance with the HWE was assessed by the chi-square test.

RESULTS
=======

The background characteristics of the subjects are shown in Table [1](#tbl01){ref-type="table"}. Men accounted for 68.7% of case subjects and 74.9% of controls. As compared with the control group, the case group had a significantly higher prevalence of heavy smokers (*P* = 0.005), a higher prevalence of a history of diabetes mellitus (*P* \< 0.001), a lower current BMI (*P* = 0.021), and a higher BMI at age 20 (*P* = 0.018).

###### Comparison of selected characteristics of pancreatic cancer (PC) patients and non-cancer controls

                                 Cases (%)     Controls (%)   *P*-values^a^
  ------------------------------ ------------- -------------- ---------------
  Age                                                         0.999
   \<40                          10 (5.41)     75 (5.12)       
   ≥40 but \<50                  19 (10.27)    147 (10.03)     
   ≥50 but \<60                  60 (32.43)    479 (32.70)     
   ≥60 but \<70                  60 (32.43)    484 (33.04)     
   ≥70                           36 (19.46)    280 (19.11)     
  Sex                                                         0.068
   Male                          127 (68.65)   1097 (74.88)    
   Female                        58 (31.35)    368 (25.12)     
  Current BMI^b^ (kg/m^2^)                                    0.021
   \<18.5                        15 (8.11)     61 (4.16)       
   ≥18.5 but \<22.5              84 (45.11)    555 (37.88)     
   ≥22.5 but \<25                47 (25.41)    478 (32.63)     
   ≥25 but \<27.5                25 (13.51)    245 (16.72)     
   ≥27.5                         14 (7.57)     111 (7.58)      
   Unknown                       0 (0.00)      15 (1.02)       
  BMI^b^ at age 20 (kg/m^2^)                                  0.018
   \<18.5                        14 (7.57)     168 (11.47)     
   ≥18.5 but \<22.5              112 (60.54)   950 (64.85)     
   ≥22.5 but \<25                36 (19.46)    226 (15.43)     
   ≥25 but \<27.5                11 (5.95)     72 (4.91)       
   ≥27.5                         6 (3.24)      14 (0.96)       
   Unknown                       6 (3.24)      35 (2.39)       
  Cigarette pack-years                                        0.005
   \<5                           69 (37.30)    638 (43.55)     
   ≥5 but \<20                   22 (11.89)    206 (14.06)     
   ≥20 but \<40                  34 (18.38)    308 (21.02)     
   ≥40                           60 (32.43)    304 (20.75)     
   Unknown                       0 (0.00)      9 (0.61)        
  Drinking, g ethanol/day                                     0.568
   Non                           56 (30.27)    488 (33.31)     
   \<23                          53 (28.65)    425 (29.01)     
   ≥23 but \<46                  43 (23.24)    342 (23.34)     
   ≥46                           31 (16.76)    193 (13.17)     
   Unknown                       2 (1.08)      17 (1.16)       
  History of diabetes mellitus                                \<0.001
   Yes                           37 (20.00)    126 (8.60)      
   No                            148 (80.00)   1339 (91.40)    
  Family history of PC                                        0.811
   Yes                           8 (4.32)      58 (3.96)       
   No                            177 (95.68)   1407 (96.04)    

^a^ *P*-values calculated by chi-square test.

^b^BMI: body mass index.

Table [2](#tbl02){ref-type="table"} shows genotype distributions for the 5 SNPs (rs1052133, rs1799782, rs25487, rs1130409, and rs1136410). Three of the 5 SNPs (rs1799782, rs25487, and rs1130409) were in accordance with HWE. The remaining 2 loci (rs1052133 and rs1136410) were not and were thus excluded from further analysis. Rs25487 in *XRCC1* was significantly associated with PC risk in the per-allele model (OR = 1.29, CI = 1.01--1.65; trend *P* = 0.043) and in the dominant model (OR = 1.39, CI = 1.01--1.91; *P* = 0.041). No significant association with PC risk was observed for the remaining 2 loci.

###### Distribution of cases and controls, and odds ratios for pancreatic cancer associated with selected BER gene polymorphisms

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Polymorphism         Genotype                                                                   No. of cases/controls\   Unadjusted ORs^a^\   Adjusted ORs^b^\
                                                                                                  (%)                      (95% CI)             (95% CI)
  -------------------- -------------------------------------------------------------------------- ------------------------ -------------------- -------------------
  rs1799782            CC                                                                         88(47.57)/677(46.21)     1.00 (ref.)          1.00 (ref.)

  (XRCC1, Arg194Trp)   CT                                                                         80(43.24)/636(43.41)     0.97 (0.70--1.33)    0.96 (0.69--1.34)

                       TT                                                                         17(9.19)/152(10.38)      0.86 (0.50--1.49)    0.81 (0.46--1.44)

                       Per-allele model                                                                                    0.94 (0.75--1.19)    0.96 (0.75--1.21)

                       Dominant model                                                                                      0.95 (0.70--1.29)    0.93 (0.68--1.28)

                       (*P* trend)                                                                                         0.622                0.709

                       minor allele(T) frequency in control subjects = 0.321 (HWE^c^: *P* = NS)                                                 

                                                                                                                                                

  rs25487              GG                                                                         93(50.27)/842(57.47)     1.00 (ref.)          1.00 (ref.)

  (XRCC1, Arg399Gln)   GA                                                                         77(41.62)/538(36.72)     1.30 (0.94--1.79)    1.36 (0.98--1.90)

                       AA                                                                         15(8.11)/85(5.80)        1.60 (0.89--2.88)    1.58 (0.85--2.93)

                       Per-allele model                                                                                    1.28 (1.00--1.63)    1.29 (1.01--1.65)

                       Dominant model                                                                                      1.34 (0.98--1.82)    1.39 (1.01--1.92)

                       (*P* trend)                                                                                         0.046                0.043

                       minor allele(A) frequency in control subjects = 0.242 (*P* = NS)                                                         

                                                                                                                                                

  rs1130409            TT                                                                         77(41.62)/542(37.00)     1.00 (ref.)          1.00 (ref.)

  (APE1, Asp148Glu)    TG                                                                         75(41.62)/681(46.48)     0.78 (0.55--1.09)    0.77 (0.55--1.10)

                       GG                                                                         33(17.84)/242(16.52)     0.96 (0.62--1.48)    1.02 (0.65--1.60)

                       Per-allele model                                                                                    0.94 (0.75--1.16)    0.96 (0.77--1.20)

                       Dominant model                                                                                      0.82 (0.60--1.12)    0.84 (0.61--1.15)

                       (*P* trend)                                                                                         0.548                0.745

                       minor allele(T) frequency in control subjects = 0.398 (*P* = NS)                                                         

                                                                                                                                                

  rs1052133            CC                                                                         55(29.73)/417(28.46)     ---                  ---

  (OGG1, Ser326Cys)    CG                                                                         87(47.03)/692(47.24)     ---                  ---

                       GG                                                                         43(23.24)/356(24.30)     ---                  ---

                       Per-allele model                                                                                    ---                  ---

                       Dominant model                                                                                      ---                  ---

                       (*P* trend)                                                                                         ---                  ---

                       minor allele(G) frequency in control subjects = 0.479 (*P* = 0.040)                                                      

                                                                                                                                                

  rs1136410            TT                                                                         61(32.97)/550(37.54)     ---                  ---

  (PARP1, Val762Ala)   TC                                                                         90(48.65)/657(44.85)     ---                  ---

                       CC                                                                         34(18.38)/258(17.61)     ---                  ---

                       Per-allele model                                                                                    ---                  ---

                       Dominant model                                                                                      ---                  ---

                       (*P* trend)                                                                                         ---                  ---

                       minor allele(T) frequency in control subjects = 0.400 (*P* = 0.012)                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: OR, odds ratio.

^a^Unconditional logistic regression model (unadjusted).

^b^Unconditional logistic regression model adjusted for age, sex, current BMI, BMI at age 20, smoking status, drinking habit, history of diabetes mellitus, and family history of pancreatic cancer.

^c^HWE: Hardy--Weinberg Equilibrium.

We analyzed potential interactions of rs1799782 and rs25487 in *XRCC1* and rs1130409 in *APE1* with known risk factors for PC, such as smoking, alcohol consumption, overweight, diabetes mellitus, and family history of PC. Because of the low frequency of minor homozygous subjects, these subjects were combined with heterozygous subjects in this analysis. The exposure variables used were current and former BMI (BMI \<25 or ≥25 kg/m^2^), alcohol consumption (\<23 or ≥23 g ethanol/day), smoking (\<5 or ≥5 PYs), heavy smoking (\<40 or ≥40 PYs), history of diabetes mellitus (yes or no), and family history of PC (yes or no). There were no statistically significant interactions ([eTable 1](#sm01){ref-type="supplementary-material"}). We also analyzed interactions of rs1799782 and rs25487 in *XRCC1* and rs1130409 in *APE1* with smoking duration and intensity and detected no statistically significant interactions ([eTable 2](#sm01){ref-type="supplementary-material"}).

Table [3](#tbl03){ref-type="table"} shows the results of haplotype analysis for *XRCC1*. The *R*-squared (*R* ^2^) value between rs1799782 and rs25487 was 0.15. Haplotype CA in *XRCC1* was associated with a statistically significant increase in PC risk (OR = 1.32, CI = 1.01--1.71; *P* = 0.042) as compared with the most common haplotype, CG, in *XRCC1*. As shown in Table [4](#tbl04){ref-type="table"}, we defined haplotype CA in *XRCC1* as a risk haplotype and analyzed the potential interactions between risk haplotype and known PC risk factors (smoking, alcohol consumption, overweight, diabetes mellitus, and family history of PC). The results showed significant interactions between a family history of PC and the risk haplotype in *XRCC1* (interaction *P* = 0.020).

###### Haplotype frequencies of *XRCC1*, and odds ratios for pancreatic cancer associated with *XRCC1* haplotype

  --------------------------------------------------------------------------------------------------------------
  Haplotype   SNPs^a^   Haplotype frequency   Adjusted OR^b^\    *P*-value                               
                                              (cases/controls\                                           
                                              185/1465)                                                  
  ----------- --------- --------------------- ------------------ ----------- ------- ------------------- -------
  1           C         G                     0.439              0.433       0.442   1.00 (ref.)          

  2           C         A                     0.240              0.274       0.239   1.32 (1.01--1.71)   0.042

  3           T         G                     0.319              0.292       0.318   1.05 (0.81--1.36)   0.691

  4           T         A                     0.002              \<0.001     0.002   N.E.                N.E.
  --------------------------------------------------------------------------------------------------------------

Abbreviation: OR, odds ratio.

^a^SNP 1 is rs1799782; SNP 2 is rs25487.

^b^Haplotype-effects logistic regression for case-control data was used. Multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC.

###### Gene-environment interaction between *XRCC1* haplotypes and selected risk factors for pancreatic cancer

  Haplotype         Exposure   Current BMI^a^      BMI^a^ at age 20    Smoking^b^          Heavy Smoking^b^    Alcohol^c^          Diabetes mellitus^d^   Family history of PC^e^
  ----------------- ---------- ------------------- ------------------- ------------------- ------------------- ------------------- ---------------------- -------------------------
  non-CA^f^         (−)        1.00 (ref.)         1.00 (ref.)         1.00 (ref.)         1.00 (ref.)         1.00 (ref.)         1.00 (ref.)            1.00 (ref.)
  CA^g^             (−)        1.37 (1.05--1.79)   1.35 (1.05--1.73)   1.64 (1.13--2.38)   1.43 (1.08--1.90)   1.30 (0.95--1.77)   1.26 (0.97--1.65)      1.20 (0.93--1.54)
                                                                                                                                                          
  non-CA^f^         (+)        1.00 (ref.)         1.00 (ref.)         1.00 (ref.)         1.00 (ref.)         1.00 (ref.)         1.00 (ref.)            1.00 (ref.)
  CA^g^             (+)        1.01 (0.59--1.73)   1.12 (0.53--2.36)   1.09 (0.80--1.50)   1.02 (0.64--1.63)   1.24 (0.85--1.82)   1.42 (0.79--2.52)      4.68 (1.59--13.81)
                                                                                                                                                          
  interaction *P*              0.468               0.124               0.095               0.097               0.729               0.864                  0.020

NOTE: All values expressed as odds ratio (95% CI). Haplotype-effects logistic regression for case-control data was used. Multivariable adjustment by age, sex, current BMI, BMI at age 20, smoking status, drinking habit, diabetes mellitus, and family history of PC. Interactions between environmental factors and genotypes were assessed by likelihood ratio tests between the logistic regression models, with and without interaction terms, between genes and environmental factors of interest.

^a^BMI \<25 vs. ≥25.

^b^Smoking: pack-years \<5 vs. ≥5; Heavy Smoking: pack-years \<40 vs. ≥40.

^c^Alcohol: g ethanol/day \<23 vs. ≥23.

^d^Diabetes mellitus: no vs. yes.

^e^Family history of pancreatic cancer: no vs. yes.

^f^Haplotype non-CA: other haplotypes (frequency \> 0.01) except haplotype CA. Frequency in control subjects was 0.760.

^g^Haplotype CA: *XRCC1* SNPs at rs1799782 and rs25487. Frequency in control subjects was 0.239.

DISCUSSION
==========

In this case-control study, we found that the genetic polymorphism rs25487 in *XRCC1* was associated with increased risk of PC in a Japanese population. However, we did not detect any statistically significant interactions with smoking.

The BER pathway has a primary role in the repair of oxidative base lesions such as 8-hydroxyguanine, formamidopyrimidines, and 5-hydroxyuracil.^[@r21]^ Oxidative damage to DNA may lead to mutations that activate oncogenes or inactivate tumor suppressor genes and may eventually increase the probability of genetic alterations developing into neoplastic events.^[@r21]^ Sequence variants in BER genes are thought to modulate DNA repair capacity and are consequently suspected of being associated with altered cancer risk.^[@r20]^ With regard to the association between PC risk and DNA repair pathway, genetic polymorphisms in the BER pathway are the most widely studied in Western epidemiologic studies.^[@r14]^ To our knowledge, however, this is the first study to detect an association between *XRCC1* polymorphisms and the development of PC in an Asian population.

Two common variants of *XRCC1* are rs1799782 (in which T substitutes for C) and rs25487 (in which A substitutes for G), which lead to amino acid substitutions Arg194Trp and Arg399Gln, respectively.^[@r32]^ In particular, the minor allele (A) for rs25487, namely the 399Gln allele, was found to be associated with a higher frequency of glycophorin mutant, elevated DNA adduct levels, higher baseline sister chromatid exchange frequency, and increased sensitivity to ionizing radiation, all of which might be due to reduced BER function.^[@r18]^ In the present study, the minor allele of rs25487 in *XRCC1* was associated with elevated PC risk. Thus, our finding is consistent with the potential mechanisms described above.

It has been suggested that *XRCC1* gene polymorphisms are modulating factors for PC risk, particularly in smokers.^[@r17]--[@r21]^ A synergistic effect between these gene polymorphisms and tobacco smoking in relation to PC risk has been suspected.^[@r14]^ Oxidative DNA damage produced by smoking is expected to be repaired by the BER system, which includes the *XRCC1* gene.^[@r33]^ In this study, we observed a significant main effect of rs25487 in *XRCC1* but found no statistically significant interaction between *XRCC1* loci and smoking. Although the reason for this difference is unclear, the results may have been affected by the heterogeneity of study populations, differences in ethnicity, the small sample size, and potential confounders. On the other hand, the minor allele of rs25487 in *XRCC1* was associated with increased risk of PC among light but not heavy smokers. These findings are consistent with past reports, and possible explanations for the limited effect among heavy smokers include enhanced apoptosis at the time of cell division from heavy smoking and induction of DNA repair capacity in response to DNA damage.^[@r20],[@r21]^

In addition, we found that haplotype CG in *XRCC1* had a higher impact in those with a family history of PC than in those without such a history. To our knowledge, this phenomenon has not been reported previously and might be explained by family history acting as a surrogate for interaction with known/unknown genetic susceptibility factors. We did not observe any interaction with the *ABO* genotype, which has been reported to have a significant association with PC risk (data not shown).^[@r34]^ Given our small study population, the finding of an interaction with family history may have been due to chance. Further study is required to duplicate our findings in a larger cohort.

Our study has several methodological issues that warrant discussion. First, the control population was selected from non-cancer patients at ACCH. It is reasonable to assume that this was the same population from which the case subjects were derived, which would bolster the internal validity of our study. Second, with regard to external validity, we previously showed that individuals selected randomly from our control population were similar to the general population of Nagoya City in terms of the exposure of interest.^[@r26]^ However, only 50% of patients agreed to the collection of a blood sample, and the characteristics of these participants might differ from those of the general population. Third, case-control studies have an intrinsic information bias. However, the HERPACC system is less prone to this bias than are typical hospital-based studies, as the data for all patients were collected before diagnosis. In addition, the results from our self-administered questionnaire may be inaccurate. However, any such misclassification would be nondifferential and would likely underestimate the causal association.^[@r35]^ Fourth, with regard to SNP analysis, because 2 SNPs (rs1052133 in *OGG1* and rs1136410 in *PARP1*) were not in accordance with HWE in our study, further studies that include these factors are required. Fifth, residual confounding by known and unknown risk factors might be present; given the small number of cases, our findings require replication in a larger study. Finally, our study was limited to a Japanese population, and the results cannot necessarily be extrapolated to other populations.

In summary, this case-control study showed a significant association between genetic polymorphisms in *XRCC1* and PC risk in a Japanese population. Further investigation of our findings in larger populations are warranted, and the biological mechanisms responsible for the association should be fully elucidated.
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